GERMANY - Consortium provides seed funding for Avidal Vascular

Berlin-based Avidal Vascular develops drug eluting balloons (DEB). The technology is aimed at the intraluminal drug application in coronary arteries and peripheral vessels to treat In-Stent-Restenosis (ISR), bifurcations, small vessels, and long lesions.

Avidal has previously received backing from other investors.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH